Regeneron Pharmaceuticals, Inc.

Goncalo Abecasis

Aris I Baras

Kavita Praveen

Giovanni Coppola

Lauren Gurski

Manuel Allen Revez Ferreira

Carmelo Romano

Claudia Schurmann

Tanya Teslovich Dostal

Ying Hu

Meghan Drummond Samuelson

Gaurang Patel

Eric Jorgenson

Gavin Thurston

Alexander Li

Charles Paulding

Julie Horowitz

Joshua Backman

Giusy Della Gatta

Amy Damask

Trikaldarshi Persaud

Michael Kessler

Xinyuan Zhang

Stefan Semrau

The present disclosure provides methods of reducing cardiovascular risk by administration of a PCSK9 inhibitor to patients having a genetic profile associated with response to PCSK9 inhibitor therapy.

Genome-based methods for reducing cardiovascular risk

The present disclosure provides methods of treating subjects having hearing loss, methods of identifying subjects having an increased risk of developing hearing loss, and methods of detecting Kelch Domain Containing 7B (KLHDC7B) variant nucleic acid molecules and variant polypeptides.

Kelch domain containing 7B (KLHDC7B) variants and uses thereof

The present disclosure provides methods of treating subjects having skin cancer or at risk of developing skin cancer, and methods of identifying subjects having an increased risk of developing skin cancer.

Methods of treating skin cancer with histidine ammonia-lyase (HAL) agonists

The present disclosure provides methods of treating a subject having skin cancer or preventing a subject from developing skin cancer, and methods of identifying subjects having an increased risk of developing skin cancer.

Methods of treating skin cancer with Carboxypeptidase Vitellogenic Like (CPVL) inhibitors

The present disclosure provides methods of treating subjects having inflammation with an Angiopoietin-Like 7 (ANGPTL7) inhibitor and a glucocorticoid, methods of decreasing glucocorticoid-induced ophthalmic conditions in subjects, and methods of identifying subjects having an increased risk of developing glucocorticoid-induced ophthalmic conditions.

Treatment of inflammation with glucocorticoids and angiopoietin-like 7 (ANGPTL7) inhibitors

The present disclosure provides methods of treating patients having an ophthalmic condition, methods of identifying subjects having an increased risk of developing an ophthalmic condition, methods of detecting human angiopoietin like 7 (ANGPTL7) variant nucleic acid molecules and variant polypeptides, and ANGPTL7 variant nucleic acid molecules and variant polypeptides.

Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors

The present disclosure provides methods of treating patients having an ophthalmic condition, methods of identifying subjects having an increased risk of developing an ophthalmic condition, methods of detecting human Son of Sevenless 2 (SOS2) variant nucleic acid molecules and variant polypeptides.

Treatment of ophthalmic conditions with son of Sevenless 2 (SOS2) inhibitors

Growing community of inventors

Tarrytown, NY, United States of America

Goncalo Abecasis